secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001493152-23-041524
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q3 revenue surges to $298K on PPLS acquisition; net loss narrows to $2.3M
--------------------------------------------------------------------------------

- Revenue of $298,484 for Q3 2023, up from $1,150 in prior year, primarily from acquired PPLS lab.
- Net loss of $2.3M ($0.26 per share) vs $4.9M ($1.17) in prior year; cash at $4.5M down from $11.4M.
- Acquired non-medical assets of Village Oaks Pathology Services on Sept 18, 2023; PPLS forecast to contribute $8.7M net revenue over next 12 months.
- CMS issued preliminary payment decision for CyPath Lung; final expected Nov 2023 with effective date Jan 1, 2024.
- Revenue outlook for full year 2023: $2.1-$2.3M; next 12 months: $8.4-$9.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer